{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:55Z","timestamp":1786980895201,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10620-018-5092-6","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:25:37Z","timestamp":1525307137000},"page":"1737-1746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-2156","authenticated-orcid":false,"given":"Antonio","family":"Facciorusso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarantis","family":"Livadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adwalia","family":"Fevrier-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Wekesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Dogu","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Chaurasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Sadeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Muscatiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"5092_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R Franchis de","year":"2015","unstructured":"de Franchis R, Abraldes JG, Bajaj J, et al. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743\u2013752.","journal-title":"J Hepatol"},{"key":"5092_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/liv.12593","volume":"35","author":"M Merli","year":"2015","unstructured":"Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35:362\u2013369.","journal-title":"Liver Int"},{"key":"5092_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","volume":"58","author":"T Reiberger","year":"2013","unstructured":"Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911\u2013921.","journal-title":"J Hepatol"},{"key":"5092_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","volume":"64","author":"RP Mookerjee","year":"2016","unstructured":"Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574\u2013582.","journal-title":"J Hepatol"},{"key":"5092_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","volume":"55","author":"T Serst\u00e9","year":"2011","unstructured":"Serst\u00e9 T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794\u2013799.","journal-title":"J Hepatol"},{"key":"5092_CR6","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","volume":"146","author":"M Mandorfer","year":"2014","unstructured":"Mandorfer M, Bota S, Schwabl P, et al. Nonselective b blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680\u20131690.","journal-title":"Gastroenterology"},{"key":"5092_CR7","doi-asserted-by":"publisher","unstructured":"Bossen L, Krag A, Vilstrup H, et al. Non-selective \u03b2-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three RCTs with 1198 patients. Hepatology. 2015 Nov 24. \n                    https:\/\/doi.org\/10.1002\/hep.28352\n                    \n                  . [Epub ahead of print].","DOI":"10.1002\/hep.28352"},{"key":"5092_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apt.14366","volume":"47","author":"AQ Bhutta","year":"2018","unstructured":"Bhutta AQ, Garcia-Tsao G, Reddy KR, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2018;47:78\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"5092_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","volume":"14","author":"S Chirapongsathorn","year":"2016","unstructured":"Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective \u03b2-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1096\u20131104.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5092_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","volume":"61","author":"A Krag","year":"2012","unstructured":"Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of betablockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967\u2013969.","journal-title":"Gut"},{"key":"5092_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","volume":"2","author":"A Facciorusso","year":"2017","unstructured":"Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:94\u2013102.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5092_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767\u2013777.","journal-title":"N Engl J Med"},{"key":"5092_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","volume":"60","author":"PS Ge","year":"2014","unstructured":"Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643\u2013653.","journal-title":"J Hepatol"},{"key":"5092_CR14","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2014.04.028","volume":"146","author":"PS Ge","year":"2014","unstructured":"Ge PS, Runyon BA. When should the \u03b2-blocker window in cirrhosis close? Gastroenterology. 2014;146:1597\u20131599.","journal-title":"Gastroenterology"},{"key":"5092_CR15","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \n                    www.cochrane-handbook.org\n                    \n                  . Accessed on November 30, 2017."},{"key":"5092_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u2013269.","journal-title":"Ann Intern Med"},{"key":"5092_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"5092_CR18","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle\u2014Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: \n                    http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm\n                    \n                  . Accessed on November 30, 2017."},{"key":"5092_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"5092_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u2013188.","journal-title":"Control Clin Trials"},{"key":"5092_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u2013560.","journal-title":"BMJ"},{"key":"5092_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","volume":"48","author":"A Facciorusso","year":"2016","unstructured":"Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48:571\u2013577.","journal-title":"Dig Liver Dis"},{"key":"5092_CR23","unstructured":"http:\/\/cran.r-project.org\/web\/packages\/metafor\/index.html\n                    \n                  . Accessed on November 2017."},{"key":"5092_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/jhep.2002.30418","volume":"35","author":"A Escorsell","year":"2002","unstructured":"Escorsell A, Ba\u00f1ares R, Garc\u00eda-Pag\u00e1n JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology. 2002;35:385\u2013392.","journal-title":"Hepatology"},{"key":"5092_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0016-5107(03)02819-0","volume":"59","author":"GH Lo","year":"2004","unstructured":"Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc. 2004;59:333\u2013338.","journal-title":"Gastrointest Endosc"},{"key":"5092_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jhep.2013.11.019","volume":"60","author":"HA Shah","year":"2014","unstructured":"Shah HA, Azam Z, Rauf J, et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol. 2014;60:757\u2013764.","journal-title":"J Hepatol"},{"key":"5092_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0168-8278(02)00174-5","volume":"37","author":"G Borroni","year":"2002","unstructured":"Borroni G, Salerno F, Cazzaniga M, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol. 2002;37:315\u2013321.","journal-title":"J Hepatol"},{"key":"5092_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1440-1746.2005.03982.x","volume":"21","author":"E Cholongitas","year":"2006","unstructured":"Cholongitas E, Papatheodoridis GV, Manesis EK, et al. Spontaneous bacterial peritonitis in cirrhotic patients: is prophylactic propranolol therapy beneficial? J Gastroenterol Hepatol. 2006;21:581\u2013587.","journal-title":"J Gastroenterol Hepatol"},{"key":"5092_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","volume":"52","author":"T Serst\u00e9","year":"2010","unstructured":"Serst\u00e9 T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017\u20131022.","journal-title":"Hepatology"},{"key":"5092_CR30","doi-asserted-by":"publisher","first-page":"A183","DOI":"10.1136\/gutjnl-2012-302514c.1","volume":"61","author":"AE Robins","year":"2012","unstructured":"Robins AE, Bowden A, Watson W, et al. Propanolol at modest dose does not impair survival in patients with cirrhosis and refractory ascites. Gut. 2012;61:A183.","journal-title":"Gut"},{"key":"5092_CR31","first-page":"S945","volume":"58","author":"K Mazhar","year":"2013","unstructured":"Mazhar K, ElliotT AC, Rockey DC. The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension, and ascites. Hepatology. 2013;58:S945.","journal-title":"Hepatology"},{"key":"5092_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","volume":"64","author":"JA Leithead","year":"2015","unstructured":"Leithead JA, Rajoriya N, Tehami N, et al. Non-selective \u03b2-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut.. 2015;64:1111\u20131119.","journal-title":"Gut."},{"key":"5092_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/00365521.2014.948053","volume":"50","author":"N Kimer","year":"2015","unstructured":"Kimer N, Feineis M, M\u00f8ller S, Bendtsen F. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol. 2015;50:129\u2013137.","journal-title":"Scand J Gastroenterol"},{"key":"5092_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.amjms.2015.11.018","volume":"351","author":"AW Aday","year":"2016","unstructured":"Aday AW, Mayo MJ, Elliott A, Rockey DC. The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites. Am J Med Sci. 2016;351:169\u2013176.","journal-title":"Am J Med Sci"},{"key":"5092_CR35","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/liv.13119","volume":"36","author":"UC Bang","year":"2016","unstructured":"Bang UC, Benfield T, Hyldstrup L, et al. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Liver Int. 2016;36:1304\u20131312.","journal-title":"Liver Int"},{"key":"5092_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2017.02.005","volume":"67","author":"R Sinha","year":"2017","unstructured":"Sinha R, Lockman KA, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol.. 2017;67:40\u201346.","journal-title":"J Hepatol."},{"key":"5092_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrgastro.2010.185","volume":"8","author":"JC Garcia-Pagan","year":"2011","unstructured":"Garcia-Pagan JC. Portal hypertension: nonselective [beta]- blockers in patients with refractory ascites. Nat Rev Gastroenterol Hepatol. 2011;8:10\u201311.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5092-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T19:20:20Z","timestamp":1556824820000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5092-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["5092"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5092-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733175774.793561272","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"6 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}